Free Trial
NASDAQ:CBIO

Crescent Biopharma (CBIO) Stock Price, News & Analysis

Crescent Biopharma logo
$12.96 -0.54 (-4.00%)
As of 07/11/2025 04:00 PM Eastern

About Crescent Biopharma Stock (NASDAQ:CBIO)

Key Stats

Today's Range
$12.71
$13.82
50-Day Range
N/A
52-Week Range
$11.06
$63.00
Volume
342,755 shs
Average Volume
75,383 shs
Market Capitalization
$253.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Strong Buy

Company Overview

Crescent Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

CBIO MarketRank™: 

Crescent Biopharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 364th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Crescent Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.67, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Crescent Biopharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Crescent Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Crescent Biopharma are expected to grow in the coming year, from ($0.16) to ($0.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Crescent Biopharma is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Crescent Biopharma is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Crescent Biopharma has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CBIO.
  • Dividend Yield

    Crescent Biopharma does not currently pay a dividend.

  • Dividend Growth

    Crescent Biopharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CBIO.
  • News Sentiment

    Crescent Biopharma has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Crescent Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    4 people have searched for CBIO on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Crescent Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Crescent Biopharma is held by insiders.

  • Percentage Held by Institutions

    75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Crescent Biopharma's insider trading history.
Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CBIO Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Catalyst Biosciences, Inc. (CBIO)
Catalyst Biosciences Inc trading halted, volatility trading pause
See More Headlines

CBIO Stock Analysis - Frequently Asked Questions

Crescent Biopharma's stock was trading at $15.7950 at the start of the year. Since then, CBIO shares have decreased by 17.9% and is now trading at $12.96.

Crescent Biopharma, Inc. (NASDAQ:CBIO) announced its quarterly earnings data on Thursday, August, 17th. The biopharmaceutical company reported ($7.00) earnings per share for the quarter, meeting the consensus estimate of ($7.00).

Shares of Crescent Biopharma reverse split before market open on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
8/17/2023
Today
7/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBIO
Previous Symbol
NASDAQ:CBIO
CIK
1253689
Employees
50
Year Founded
2003

Price Target and Rating

High Price Target
$28.00
Low Price Target
$22.00
Potential Upside/Downside
+92.9%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($46.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.88 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-293.92%
Return on Assets
-206.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.29
Quick Ratio
2.29

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.24 per share
Price / Book
1.57

Miscellaneous

Outstanding Shares
19,550,000
Free Float
18,768,000
Market Cap
$253.37 million
Optionable
No Data
Beta
1.52

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CBIO) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners